Key Market Indicators
Estonian sales of antihypertensive medicine are set to reach $2 million by 2026. In 2021, sales reached $1.8 million, growing at a rate of nearly 3% each year. Since 2004, demand in Estonia has grown 17% annually. In 2021, Estonia ranked 23rd in sales. New Zealand was ahead with $1.8 million, while Italy, Spain and Australia ranked second, third and fourth, respectively.
